Understanding NASH

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease characterized by the accumulation of fat in the liver, inflammation, and liver cell damage. It is often associated with obesity, type 2 diabetes, and high cholesterol. While the exact cause of NASH remains unknown, it is a significant health concern that can lead to serious liver complications, including cirrhosis and liver cancer.

Market Dynamics

The NASH market is driven by several factors:

• Rising Prevalence of Obesity and Diabetes: The increasing incidence of obesity and type 2 diabetes, two major risk factors for NASH, is fueling market growth.
• Aging Population: As the global population ages, the prevalence of chronic liver diseases, including NASH, is on the rise.
• Increased Awareness and Early Diagnosis: Growing awareness of NASH and advancements in diagnostic tools are enabling earlier detection and intervention.
• Pipeline of Therapeutic Options: A robust pipeline of drugs targeting NASH, including both small-molecule and biologic therapies, is expected to drive market growth.
• Government Initiatives and Funding: Governments worldwide are investing in research and development to address the growing burden of NASH, further stimulating market growth.

Source: The Insight Partners